RCKT Earnings Date: Nov 5, 2026 (Estimated) — Rocket Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RCKT's next earnings date?
Rocket Pharmaceuticals, Inc. (RCKT) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.39 on revenue of $200,000.
How did RCKT do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Rocket Pharmaceuticals, Inc. posted EPS of -$0.37 versus the $0.86 estimate, a miss of 208.8%. Revenue was $0 against a $18.2M estimate. The stock's 1-day post-earnings move was -3.8%.
How much does RCKT stock move after earnings?
RCKT beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.7% (up or down) in the day after earnings.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | 0.86 | -0.37 | -208.82% | $0 | ❌ Miss | -3.85% | -6.59% | -0.27% |
| 2026-05-07 | Q1 2026 | -0.44 | -0.42 | +4.55% | $0 | ✅ Beat | -1.09% | -7.36% | -26.43% |
| 2026-02-26 | Q4 2025 | -0.42 | -0.38 | +9.52% | $0 | ✅ Beat | +10.60% | +2.43% | -16.78% |
| 2025-11-06 | Q3 2025 | -0.50 | -0.45 | +10.00% | $0 | ✅ Beat | -1.86% | -1.86% | +8.36% |
| 2025-08-07 | Q2 2025 | -0.55 | -0.62 | -12.73% | $0 | ❌ Miss | -7.44% | -1.94% | +5.50% |
| 2025-02-27 | Q4 2024 | -0.72 | -0.62 | +13.89% | $0 | ✅ Beat | +0.53% | -4.36% | -19.26% |
| 2024-11-07 | Q3 2024 | -0.76 | -0.71 | +6.58% | $0 | ✅ Beat | +1.16% | -14.09% | -19.77% |
| 2024-02-26 | Q4 2023 | -0.79 | -0.64 | +18.99% | $0 | ✅ Beat | +3.19% | -3.63% | -10.84% |
Showing last 8 quarters.